Login / Signup
–Compared to dabigatran, rivaroxaban was associated with more intracranial and other serious bleeds. A new observational study finds that patients who take rivaroxaban (Xarelto, Johnson…
More Questions Raised About Boehringer Ingelheim’s Pradaxa
Once again dabigatran (Pradaxa) has raised the wrath of the critics. Several articles and an editorial published today in The BMJ raise more questions and concerns about…
Boehringer Ingelheim Settles US Pradaxa Litigation For $650 Million
Boehringer Ingelheim said today that it will pay $650 million in a “comprehensive settlement” of lawsuits over Pradaxa (dabigatran), the company’s novel anticoagulant. The company said that…
FDA Study Provides Some Reassurance About Boehringer Ingelheim’s Pradaxa
In the latest development in its ongoing review of the new oral anticoagulant dabigatran (Pradaxa, Boehringer Ingelheim), the FDA today offered largely reassuring news about the…
Boehringer Ingelheim’s Pradaxa Gains New Indication
The new oral anticoagulants continue to gain additional indications from the FDA. Earlier today Boehringer Ingelheim announced that the FDA had approved Pradaxa (dabigatran) for the treatment…
Registry Study Offers Reassurance About Safety And Efficacy Of Dabigatran
As the first new oral anticoagulant since warfarin, dabigatran (Pradaxa, Boehringer-Ingelheim) has been subject to intense concerns over its safety and efficacy in a real-world population.…
FDA Officials Calm Concerns Over Excessive Bleeding With Dabigatran
Concerns over excessive bleeding complications with dabigatran (Pradaxa, Boehringer Ingelheim) as compared with warfarin are most likely due to the heightened sensitivity and vigilance that…
Two Experts Help Sort Out The New Generation Of Anticoagulants
Don’t miss this very practical discussion about the new generation of anticoagulants and the short term loan costs to cover them over on CardioExchange. Here are a…
Pradaxa To Be Contraindicated In Patients With Mechanical Heart Valves
Boehringer Ingelheim is starting to inform physicians about a new contraindication for its oral anticoagulant drug Pradaxa (dabigatran). The company has told investigators in trials…
Boehringer Ends Phase 2 Trial Of Dabigatran In Mechanical Valve Patients
Boehringer Ingelheim today announced that it had discontinued a phase 2 trial of its anticoagulant drug dabigatran (Pradaxa) in patients with mechanical heart valves. As…